Immunovia: Immray Pancan-d Approaches The Market
Edison | Mar 22, 2018 05:59AM ET
Immunovia publ AB (ST:IMMNOV) is preparing to market its IMMray PanCan-d for self-pay patients at high risk of pancreatic cancer (PC) in Q418, after preparatory activities were pushed back slightly from mid-2017 to 2018. To achieve reimbursement, a prospective trial in this population is being run and if positive, the test could be reimbursed in 2020. Immunovia is pursuing other groups ie patients with new-onset T2 diabetes aged 50+ and those with early gastric symptoms. Our revised valuation is SEK3.6bn as we now include early gastric symptoms. Autoimmune diseases represent upside.
First self-pay sales in sight in high-risk patients
Immunovia plans to market its lead indication the IMMray PanCan-d test in late 2018 in the private self-pay market following a slight delay to its pre-marketing activities from mid-2017 to this year. The company is also running the PANFAM-1 study, a three-year prospective clinical trial in 1,000 high-risk patients to achieve reimbursement. At SEK5,000/test and two tests per year, we estimate the total market opportunity is c SEK2bn in the EU/US, based on c 200k potential patients.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.